Two new broker notes out last week on this one -

Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share

Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED

Have a look

StockMarketWire.com
Angle plc, a world-leading liquid biopsy company, reported revenues of £0.2m for the six months ended 31 October 2017 but losses from continuing operations widened to £3.4m.

The company noted several important operational highlights for the period including clinical evidence from successful US and European ovarian cancer studies in 400 patients.

While the acquisition of Axela for £3.6 million was said to have expanded the company's liquid biopsy capabilities. Extensive work toward FDA Class II clearance in metastatic breast cancer was completed.

Angle grew its installed base to over 145 Parsortix instruments worldwide (H1 2017: 120) with over 39,000 blood separations completed (H1 2017: 22,000).

Garth Selvey, Chairman, said:

"Angle has continued to make excellent progress in executing its strategy for commercialisation of the Parsortix system, and its adoption as a gold standard in liquid biopsy, during the first half of the year.'

'We have successfully completed two large scale ovarian cancer clinical studies, progressed our FDA studies, broadened our liquid biopsy capabilities to include a downstream analysis platform with the acquisition of assets of Axela, and secured corporate partnerships with two leading, global healthcare companies.'

'Our pivotal US FDA analytical and clinical studies in metastatic breast cancer are expected to complete in H2 CY 2018.'

'Angle is seeking to become the first company to receive FDA clearance for a product for harvesting intact circulating cancer cells from patient blood for subsequent analysis.'

'We believe this will differentiate ANGLE in the liquid biopsy market and will have a major positive impact, driving the business forward on numerous fronts.'

Important news from this company......if this is correct : could be a game changer.....

Yes - off of yesterday's highs atm, but potentially a fantastic break through.

Most people won't have yet spotted the what seems great news about the breakthrough in defeating cancer....if this is correct ; it is remarkable !.....

Surprised that the sp is not much..much...higher...why are people selling this with incredible news....???

It had a massive rise yesterday on the news!

For about 5mn......strange time to realease an rns….some companies do that ….problem is the general public can miss the rns……..anyway...we shall see : one to watch now.....

RF,

Advancement appears to be in "diagnosis" or "recognising" variants of "ovarian cancer".

That may improve subsequent "treatments" of such, but the technique is not the "cure" but could be a first stage towards one.

(Could be wrong in my interpretation.)

Fred :.....it looks like a cure....99%...in mice...and now testing humans....in Switzerland trials....a system like this gets commercialised and the sky is the limit for this company......the big boys would want to buy this firm then.....

Link copied :- Biotech minnow Angle triumphs with cancer blood testing kit

More good news....could be a real winner this year, this company....

Had a few last week.

Looks promising.

£1 by xmas :-)